Zydus Lifesciences' shares dipped 2% after completing the $166.4 million acquisition of US-based Assertio Holdings Inc. The deal, finalized through a subsidiary, makes Assertio a wholly-owned entity, bolstering Zydus's specialty and oncology supportive-care therapies pipeline. This strategic move aims to enhance the company's innovative drug offerings.

Read the Full Story

This is a syndicated news brief. To read the complete, unabridged article and see all related media, please visit the original publisher.

Continue Reading on Economic Times

Need Fintech Engineering?

Book a free architecture session with our technical team.

Schedule a Call

Looking to Build Your Own Platform?

Get expert guidance on building compliant and scalable wealthtech platforms.

Schedule a Call